[go: up one dir, main page]

HUP0100991A2 - 1'-[4-[1-(4-Fluorfenil)-1H-indol-3-il]-1-butil]-spiro[izobenzofurán-1(3H),4'-piperidin]-hidrohalogenidek, és alkalmazásuk gyógyászati készítményekben - Google Patents

1'-[4-[1-(4-Fluorfenil)-1H-indol-3-il]-1-butil]-spiro[izobenzofurán-1(3H),4'-piperidin]-hidrohalogenidek, és alkalmazásuk gyógyászati készítményekben Download PDF

Info

Publication number
HUP0100991A2
HUP0100991A2 HU0100991A HUP0100991A HUP0100991A2 HU P0100991 A2 HUP0100991 A2 HU P0100991A2 HU 0100991 A HU0100991 A HU 0100991A HU P0100991 A HUP0100991 A HU P0100991A HU P0100991 A2 HUP0100991 A2 HU P0100991A2
Authority
HU
Hungary
Prior art keywords
spiro
piperidine
butyl
fluorophenyl
isobenzofuran
Prior art date
Application number
HU0100991A
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Niels Mork
Ole Nielsen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HUP0100991A2 publication Critical patent/HUP0100991A2/hu
Publication of HUP0100991A3 publication Critical patent/HUP0100991A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány az (I) képletű 1'-[4-[1-(4-fluorfenil)-1H-indol-3-il]-1-butil]-spiro[izo-benzofurán-1(3H),4'-piperidin] hidrogénkloriddal,hidrogénbromiddal vagy hidrogénjodiddal képzett hidrohalogenidjeire,ilyen savaddíciós sókat tartalmazó gyógyászati készítményekre,valamint az említett savaddíciós sóknak pszichikai és neurológiairendellenességek, például szorongás, pszichózis, epilepszia, görcsösállapotok, mozgási rendellenességek, motoros rendellenességek,amnézia, cerebrovaszkuláris megbetegedések, Alzheimer-kór típusúöregkori elmebaj és Parkinson-kór kezelésére alkalmas gyógyászatikészítmények előállításánál való alkalmazására vonatkozik. Ó

Claims (6)

  1. -14Szabadalmi igénypontok:
    1. Az 1 ’-[4-[ 1 -(4-fIuorfeniI)-1 H-indol-3-iI]-1 -butil]-spiro[izobenzofurán-1(3H),4’-piperidin] hidrohalogenidsói, valamint ezeknek a sóknak hidrátjai és/vagy szolvátjai.
    Az 1. igénypont szerinti hidrohalogenidsók közül az 1’-[4-[1-(4-fluorfenil)-1 H-indol-3-il]-1-butil]-spiro[izobenzofurán-1(3H),4’-piperidin] hidrokloridsója, valamint ennek hidrátjai és/vagy szolvátjai.
  2. 3. Gyógyászati készítmény, amely hatóanyagként az 1. igénypont szerinti hidrohalogenidsót tartalmaz a gyógyszergyártásban szokásosan használt hordozó-, hígító- és/vagy egyéb segédanyagokkal együtt kombinációban.
  3. 4. A 3. igénypont szerinti gyógyászati készítmény, amely hidrohalogenidsóként hidrokloridsót tartalmaz.
  4. 5. Az 1. igénypont szerinti hidrohalogenidsók alkalmazása szorongás, pszichózis, epilepszia, görcsös állapotok, mozgási rendellenességek, motoros zavarok, amnézia, cerebrovaszkuláris megbetegedések, Alzheimer-kór típusú öregkori elmebaj vagy Parkinson-kór kezelésére alkalmas gyógyászati készítmények előállításánál.
  5. 6. Az 5. igénypont szerinti alkalmazás, ahol a megbetegedés szorongás.
  6. 7. Az 5. vagy 6. igénypont szerinti alkalmazás, ahol hidrohalogenidsóként hidrokloridsó kerül felhasználásra.
    A bejelentő helyett a meghatalmazott:
    Ff \ Ί
    Áöefp$A s? iiuispeqBzs aL \ vianwa
    Molnár Imre szabadalmi ügyvivő
    Aktaszámunk: 92054-3086 -
HU0100991A 1997-11-07 1998-11-06 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]hydrohalogenides and their use in pharmaceutical compositions HUP0100991A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK126797 1997-11-07
PCT/DK1998/000480 WO1999024436A1 (en) 1997-11-07 1998-11-06 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl] -1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine] hydrohalogenides

Publications (2)

Publication Number Publication Date
HUP0100991A2 true HUP0100991A2 (hu) 2001-09-28
HUP0100991A3 HUP0100991A3 (en) 2003-03-28

Family

ID=8102935

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100991A HUP0100991A3 (en) 1997-11-07 1998-11-06 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]hydrohalogenides and their use in pharmaceutical compositions

Country Status (38)

Country Link
US (2) US6844352B2 (hu)
EP (1) EP1044202B1 (hu)
JP (1) JP3605358B2 (hu)
KR (1) KR100399274B1 (hu)
CN (1) CN1105115C (hu)
AR (1) AR023010A1 (hu)
AT (1) ATE288918T1 (hu)
AU (1) AU749094B2 (hu)
BG (1) BG64906B1 (hu)
BR (1) BR9813949A (hu)
CA (1) CA2308745C (hu)
CZ (1) CZ288666B6 (hu)
DE (1) DE69828999T2 (hu)
DZ (1) DZ2642A1 (hu)
EA (1) EA002092B1 (hu)
EG (1) EG23791A (hu)
ES (1) ES2234162T3 (hu)
HR (1) HRP20000261B1 (hu)
HU (1) HUP0100991A3 (hu)
ID (1) ID25776A (hu)
IL (1) IL135723A (hu)
IS (1) IS2342B (hu)
JO (1) JO2052B1 (hu)
MA (1) MA25585A1 (hu)
NO (1) NO325920B1 (hu)
NZ (1) NZ504065A (hu)
PE (1) PE130299A1 (hu)
PL (1) PL190538B1 (hu)
PT (1) PT1044202E (hu)
RS (1) RS49777B (hu)
SK (1) SK285245B6 (hu)
TN (1) TNSN98201A1 (hu)
TR (1) TR200001267T2 (hu)
TW (1) TW483894B (hu)
UA (1) UA64769C2 (hu)
UY (1) UY25236A1 (hu)
WO (1) WO1999024436A1 (hu)
ZA (1) ZA9810116B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030453A1 (es) * 2000-08-15 2003-08-20 Lundbeck & Co As H Composicion farmaceutica con contenido de 1' [4-[1-(4-fluorofenil)-1h-indol-3-il]-1-butil] espiro [isobenzofuran-1 (3h), 4'-piperidina]
AU2003263155A1 (en) * 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
WO2004110388A2 (en) 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
WO2007012319A1 (de) * 2005-07-29 2007-02-01 Sigma-Aldrich Production Gmbh Ionisierungsadditive enthaltende lc/ms-blends
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
IL135723A0 (en) 2001-05-20
NZ504065A (en) 2002-05-31
IL135723A (en) 2005-11-20
MA25585A1 (fr) 2002-12-31
CZ20001663A3 (cs) 2000-10-11
CN1278823A (zh) 2001-01-03
AU1022699A (en) 1999-05-31
HRP20000261A2 (en) 2001-04-30
CZ288666B6 (cs) 2001-08-15
BG64906B1 (bg) 2006-08-31
JP3605358B2 (ja) 2004-12-22
PT1044202E (pt) 2005-04-29
US20030055074A1 (en) 2003-03-20
NO20002188D0 (no) 2000-04-27
BR9813949A (pt) 2000-09-26
ZA9810116B (en) 1999-05-07
CN1105115C (zh) 2003-04-09
AU749094B2 (en) 2002-06-20
TR200001267T2 (tr) 2000-09-21
PE130299A1 (es) 1999-12-16
KR20010031791A (ko) 2001-04-16
UA64769C2 (uk) 2004-03-15
UY25236A1 (es) 2000-12-29
HK1034075A1 (en) 2001-10-12
RS49777B (sr) 2008-06-05
EP1044202B1 (en) 2005-02-09
ES2234162T3 (es) 2005-06-16
ATE288918T1 (de) 2005-02-15
ID25776A (id) 2000-11-02
US6844352B2 (en) 2005-01-18
YU23500A (sh) 2003-12-31
DZ2642A1 (fr) 2004-12-28
JO2052B1 (en) 1999-05-15
EA002092B1 (ru) 2001-12-24
KR100399274B1 (ko) 2003-09-26
PL190538B1 (pl) 2005-12-30
HUP0100991A3 (en) 2003-03-28
SK285245B6 (sk) 2006-09-07
IS2342B (is) 2008-02-15
AR023010A1 (es) 2002-09-04
EA200000502A1 (ru) 2000-10-30
CA2308745C (en) 2004-01-20
EG23791A (en) 2007-08-13
JP2001522852A (ja) 2001-11-20
NO325920B1 (no) 2008-08-18
IS5460A (is) 2000-04-18
WO1999024436A1 (en) 1999-05-20
US20050171135A1 (en) 2005-08-04
TW483894B (en) 2002-04-21
TNSN98201A1 (fr) 2005-03-15
SK6462000A3 (en) 2000-10-09
BG104485A (en) 2001-01-31
DE69828999D1 (de) 2005-03-17
DE69828999T2 (de) 2005-07-21
CA2308745A1 (en) 1999-05-20
HRP20000261B1 (en) 2009-04-30
PL340220A1 (en) 2001-01-15
NO20002188L (no) 2000-06-14
EP1044202A1 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
HUP0100991A2 (hu) 1'-[4-[1-(4-Fluorfenil)-1H-indol-3-il]-1-butil]-spiro[izobenzofurán-1(3H),4'-piperidin]-hidrohalogenidek, és alkalmazásuk gyógyászati készítményekben
CN110177581B (zh) 髓过氧化物酶显像剂
US20150218111A1 (en) Fluoroalkyl-1,4-benzodiazepinone compounds
CA2903107A1 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
DE60128587T2 (de) Lactamverbindungen
CA2904403A1 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
CA2962206A1 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
EP0427636A2 (en) 4-Acylaminopyridine derivatives
JP2013532125A (ja) カルシウムチャネルに対する親和性を有するスピロ環誘導体
US20240262823A1 (en) Pharmaceutically acceptable salt of pyrazoloheteroaryl derivative and crystal form thereof
CN107304188A (zh) 一种氘代激酶选择性抑制剂及其应用
US20250154126A1 (en) Crystalline form of sulfur-containing isoindoline derivative
WO2025180517A1 (zh) 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途
HK40075865A (en) Compounds having tyk2 inhibitory activity, pharmaceutical composition comprising the same, and use thereof
CN120569387A (zh) Par2的小分子调节剂及其用途
CN121159455A (zh) 氨基酯类化合物及其作为p2x7拮抗剂的用途
MXPA00004094A (en) 1'-[4-[1- (4-fluorophenyl)- 1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran- 1(3h),4'- piperidine]hydrohalogenides
HK1034075B (en) 1'-[4-[1-(4-fluorophenyl)- 1h-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3h),4'-piperidine] hydrohalogenides

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees